2020.03.13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)
2020.01.18 2020.1-Biocentury: I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma
2020.01.03 I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China
2019.11.14 I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China
2019.10.14 I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China